Endocrinopathy complications and the role of serum ferritin as a marker of endocrinopathy prediction in patients with beta-thalassemia major
Background: This study aimed to estimate the prevalence of complications and in β-thalassemia patients, to identify its related risk factors and to determine the optimal thresholds of serum ferritin and disease duration as a predictor of the endocrine disease. Materials and Methods: A total of 140 p...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Advances in Human Biology |
Subjects: | |
Online Access: | http://www.aihbonline.com/article.asp?issn=2321-8568;year=2018;volume=8;issue=3;spage=169;epage=174;aulast=Eshaqh-hosseini |
id |
doaj-502058d66bd7497d87e95b6eaf0ab255 |
---|---|
record_format |
Article |
spelling |
doaj-502058d66bd7497d87e95b6eaf0ab2552020-11-24T21:30:05ZengWolters Kluwer Medknow PublicationsAdvances in Human Biology2321-85682348-46912018-01-018316917410.4103/AIHB.AIHB_18_18Endocrinopathy complications and the role of serum ferritin as a marker of endocrinopathy prediction in patients with beta-thalassemia majorSeyed Kamal Eshaqh-hosseiniTohid Jafari-KoshkiShahram Arsang-JangJavad ShapouriBackground: This study aimed to estimate the prevalence of complications and in β-thalassemia patients, to identify its related risk factors and to determine the optimal thresholds of serum ferritin and disease duration as a predictor of the endocrine disease. Materials and Methods: A total of 140 patients with β-thalassemia major, 65 (46.4%) male with a mean age of 21.4 ± 7.5 (range 8–39) years were enrolled in this study. Logistic regression and receiver operating characteristic curve were used to estimate the diagnostic power of ferritin level and determine the optimal cut points. Results: The serum ferritin level was 3395 ± 2611 μg/L with stable trend across the last 5 years. Puberty delay was the most common complication with the prevalence of 33.6%. There was a significant association between ferritin levels and hypocalcaemia (odds ratio [OR] = 1.29, P = 0.001), short stature (OR = 1.04, P < 0.001) and puberty delay (OR = 1.02, P = 0.002). A >2100 μg/L and >3400 μg/L optimal cut-off values of serum ferritin level for puberty delay was 2100 area under the curve (AUC = 0.78, P = 0.004) and 3400 for short stature (AUC = 0.74, P < 0.0001). Conclusions: Progressive deterioration of endocrine dysfunction and inadequacy of chelation therapy in older patients are endocrine complications amongst beta-thalassemia major patients that need more attention. Prosperous control of the ferritin levels before puberty with deferoxamine appeared to be an effective treatment to prevent and reduce diabetes and hypothyroidism. The serum ferritin >1500 μg/L along with early second decade of illness is the best predictor for the development the endocrinopathy.http://www.aihbonline.com/article.asp?issn=2321-8568;year=2018;volume=8;issue=3;spage=169;epage=174;aulast=Eshaqh-hosseiniDiabeteshypocalcemiaIranIron overloadpubertal delay |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Seyed Kamal Eshaqh-hosseini Tohid Jafari-Koshki Shahram Arsang-Jang Javad Shapouri |
spellingShingle |
Seyed Kamal Eshaqh-hosseini Tohid Jafari-Koshki Shahram Arsang-Jang Javad Shapouri Endocrinopathy complications and the role of serum ferritin as a marker of endocrinopathy prediction in patients with beta-thalassemia major Advances in Human Biology Diabetes hypocalcemia Iran Iron overload pubertal delay |
author_facet |
Seyed Kamal Eshaqh-hosseini Tohid Jafari-Koshki Shahram Arsang-Jang Javad Shapouri |
author_sort |
Seyed Kamal Eshaqh-hosseini |
title |
Endocrinopathy complications and the role of serum ferritin as a marker of endocrinopathy prediction in patients with beta-thalassemia major |
title_short |
Endocrinopathy complications and the role of serum ferritin as a marker of endocrinopathy prediction in patients with beta-thalassemia major |
title_full |
Endocrinopathy complications and the role of serum ferritin as a marker of endocrinopathy prediction in patients with beta-thalassemia major |
title_fullStr |
Endocrinopathy complications and the role of serum ferritin as a marker of endocrinopathy prediction in patients with beta-thalassemia major |
title_full_unstemmed |
Endocrinopathy complications and the role of serum ferritin as a marker of endocrinopathy prediction in patients with beta-thalassemia major |
title_sort |
endocrinopathy complications and the role of serum ferritin as a marker of endocrinopathy prediction in patients with beta-thalassemia major |
publisher |
Wolters Kluwer Medknow Publications |
series |
Advances in Human Biology |
issn |
2321-8568 2348-4691 |
publishDate |
2018-01-01 |
description |
Background: This study aimed to estimate the prevalence of complications and in β-thalassemia patients, to identify its related risk factors and to determine the optimal thresholds of serum ferritin and disease duration as a predictor of the endocrine disease. Materials and Methods: A total of 140 patients with β-thalassemia major, 65 (46.4%) male with a mean age of 21.4 ± 7.5 (range 8–39) years were enrolled in this study. Logistic regression and receiver operating characteristic curve were used to estimate the diagnostic power of ferritin level and determine the optimal cut points. Results: The serum ferritin level was 3395 ± 2611 μg/L with stable trend across the last 5 years. Puberty delay was the most common complication with the prevalence of 33.6%. There was a significant association between ferritin levels and hypocalcaemia (odds ratio [OR] = 1.29, P = 0.001), short stature (OR = 1.04, P < 0.001) and puberty delay (OR = 1.02, P = 0.002). A >2100 μg/L and >3400 μg/L optimal cut-off values of serum ferritin level for puberty delay was 2100 area under the curve (AUC = 0.78, P = 0.004) and 3400 for short stature (AUC = 0.74, P < 0.0001). Conclusions: Progressive deterioration of endocrine dysfunction and inadequacy of chelation therapy in older patients are endocrine complications amongst beta-thalassemia major patients that need more attention. Prosperous control of the ferritin levels before puberty with deferoxamine appeared to be an effective treatment to prevent and reduce diabetes and hypothyroidism. The serum ferritin >1500 μg/L along with early second decade of illness is the best predictor for the development the endocrinopathy. |
topic |
Diabetes hypocalcemia Iran Iron overload pubertal delay |
url |
http://www.aihbonline.com/article.asp?issn=2321-8568;year=2018;volume=8;issue=3;spage=169;epage=174;aulast=Eshaqh-hosseini |
work_keys_str_mv |
AT seyedkamaleshaqhhosseini endocrinopathycomplicationsandtheroleofserumferritinasamarkerofendocrinopathypredictioninpatientswithbetathalassemiamajor AT tohidjafarikoshki endocrinopathycomplicationsandtheroleofserumferritinasamarkerofendocrinopathypredictioninpatientswithbetathalassemiamajor AT shahramarsangjang endocrinopathycomplicationsandtheroleofserumferritinasamarkerofendocrinopathypredictioninpatientswithbetathalassemiamajor AT javadshapouri endocrinopathycomplicationsandtheroleofserumferritinasamarkerofendocrinopathypredictioninpatientswithbetathalassemiamajor |
_version_ |
1725963955637059584 |